CanSino

Markiert sind besonders wichtige Quellen.

• Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-contr

  thelancet.com, hinzugefügt am 29.12.2021

• Clinical trials approved for CanSino’s inhaled COVID-19 vaccine

  globaltimes.cn, hinzugefügt am 24.03.2021

• China's CanSino Biologics COVID-19 vaccine receives emergency use approval in Hungary

  reuters.com, hinzugefügt am 22.03.2021

• China’s CanSino COVID-19 vaccine shows 75% efficacy in Pakistan

  gulfnews.com, hinzugefügt am 10.02.2021

• Third Chinese Covid-19 Vaccine Was 66% Effective in Late-Stage Study

  wsj.com, hinzugefügt am 09.02.2021

• Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

  thelancet.com, hinzugefügt am 04.02.2021

• Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

  thelancet.com, hinzugefügt am 04.02.2021

• 3 Impfstoffe aus China drängen auf weltweiten Einsatz

  aerzteblatt.de, hinzugefügt am 04.02.2021

• China CanSinoBIO's COVID-19 vaccine trials recruit over 20,000 people

  reuters.com, hinzugefügt am 22.12.2020

Keine Quelle enthält diesen Text.